01
Commercial
NYKD: Nykode Therapeutics Presents Comprehensive Preclinical Data, Optimized Manufacturing, and Durable Clinical Immunogenicity for their Individualized Neoantigen Therapy VB10.NEO - Finansavisen
Nykode Therapeutics presented preclinical data, manufacturing optimizations, and durable clinical immunogenicity for its individualized neoantigen therapy VB10.NEO. The presentation highlights the company's progress in scaling production and demonstrating sustained immune responses in clinical settings. This update signals continued development momentum for Nykode’s platform technology.